Mar 17 |
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
|
Mar 16 |
Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
|
Mar 14 |
Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter
|
Mar 14 |
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
|
Mar 14 |
Akebia GAAP EPS of $0.00 beats by $0.04, revenue of $56.2M beats by $0.81M
|
Mar 14 |
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
Mar 14 |
Earnings Scheduled For March 14, 2024
|
Mar 11 |
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
|
Jan 30 |
Akebia Therapeutics closes up to $55M loan facility
|
Jan 30 |
Akebia Secures $55 Million Term Loan Financing
|